A pivotal trial on orforglipron, a daily weight-loss pill, demonstrated significant results for participants, who lost an average of 7.3kg over nine months. The phase 3 clinical trial, involving 559 patients with type 2 diabetes from multiple countries, showcased the drug's ability to reduce blood sugar levels significantly. Eli Lilly, the manufacturer, expressed optimism about the pill's potential for widespread use, offering a more convenient option than current injections. With rising obesity rates and diabetes prevalence, orforglipron could be a game-changer in obesity and diabetes management.
The trial showed that taking a daily pill of 3mg, 12mg or 36mg reduced blood sugar by 1.2% to 1.5%, while participants lost up to 7.6% of their weight.
David Ricks, the Eli Lilly CEO, mentioned that orforglipron, as a convenient once-daily pill, may provide a new option for people around the world.
The trial, which enrolled 559 obese individuals with type 2 diabetes, revealed consistent results that met expectations on safety and efficacy.
With two-thirds of adults in Britain either overweight or living with obesity, orforglipron could potentially broaden access to effective obesity management.
Collection
[
|
...
]